Literature DB >> 16381624

Reducing the global breast cancer burden: the importance of patterns of care research.

Kathy S Albain1, Jaime de la Garza Salazar, Tadeusz Pienkowski, Matti Aapro, Jonas Bergh, Maira Caleffi, Robert Coleman, Wolfgang Eiermann, Fikri Icli, Mark Pegram, Martine Piccart, Raymond Snyder, Masakazu Toi, Gabriel N Hortobagyi.   

Abstract

Breast cancer treatment guidelines are not uniformly followed in clinical practice, with evidence for substantial variations in treatment patterns, quality of care, and patient outcomes among and within countries. The factors that drive treatment decisions are unclear. Furthermore, the impact of different treatment strategies on survival is poorly understood outside the clinical trial setting. Sources of patterns of care information often have limitations in completeness, quality, timeliness of reporting, and relevance to the larger population. Patterns of care studies frequently lack details on cancer stage at diagnosis, tumor biology, and treatment received. It is difficult to compare data between studies and/or track changes over time because of variations in data sources and collection techniques. Thus, the design and implementation of a global registry is sorely needed in order to prospectively evaluate worldwide patterns of care and outcomes in patients with breast cancer. Components of this registry should include random selection of centers of variable practice settings in multiple countries and accurate and rapid data reporting at prestudy and follow-up timepoints. Data collected would include tumor and demographic factors, staging information, treatment rendered, and survival. Variables that influenced the treatment selected would be assessed. This unique international effort would allow the development of strategies to improve diagnostic and treatment-related standards of care and survival outcomes, thus reducing the breast cancer burden worldwide.

Entities:  

Mesh:

Year:  2005        PMID: 16381624     DOI: 10.3816/CBC.2005.n.045

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  6 in total

1.  A pooled analysis of gemcitabine plus docetaxel versus capecitabine plus docetaxel in metastatic breast cancer.

Authors:  Andrew D Seidman; Stephen Chan; Jin Wang; Chao Zhu; Cong Xu; Binghe Xu
Journal:  Oncologist       Date:  2014-04-04

2.  A systematic review of gemcitabine and taxanes combination therapy randomized trials for metastatic breast cancer.

Authors:  Qian Hu; Jun-Xia Jiang; Long Luo; Xing Yang; Xiao Lin; Xiao-Xiao Dinglin; Wei Zhang; Jun-Yan Wu; He-Rui Yao
Journal:  Springerplus       Date:  2014-06-11

3.  Cardiac safety of the adjuvant Trastuzumab in a Moroccan population: observational monocentric study of about 100 patients.

Authors:  Meryem Aitelhaj; Siham Lkhouyaali; Ghizlane Rais; Amina Mohtaram; Soundouss Raissouni; Brahim Ghissassi; Saber Boutayeb; Hind Mrabti; Youssef Bensouda; Hassan Errihani
Journal:  BMC Res Notes       Date:  2013-08-28

4.  Vinorelbine with or without Trastuzumab in Metastatic Breast Cancer: A Retrospective Single Institution Series.

Authors:  Athina Stravodimou; Khalil Zaman; Ioannis A Voutsadakis
Journal:  ISRN Oncol       Date:  2014-03-30

5.  Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer: A Retrospective Study.

Authors:  Jinyu Li; Junhao You; Wen Si; Yanyun Zhu; Yi Chen; Bo Yang; Chun Han; Ruixia Linghu; Xingyang Zhang; Shunchang Jiao; Junlan Yang
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817

6.  Quality of Breast Cancer Treatment at a Rural Cancer Center in Rwanda.

Authors:  Daniel S O'Neil; Nancy L Keating; Jean Marie V Dusengimana; Vedaste Hategekimana; Aline Umwizera; Tharcisse Mpunga; Lawrence N Shulman; Lydia E Pace
Journal:  J Glob Oncol       Date:  2017-05-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.